SPECIFIC ARTICLES AVAILABLE FOR DOWNLOAD AND BULK REPRINT
FOR ANY QUESTIONS PLEASE CONTACT THE PUBLISHER – ceo@medworksmedia.com
T.E.N Vol. 2 No. 2 – Jack Gorman’s Schizophrenia Endowment
IN THIS ISSUE:
- 5 – Journal Mission/Objectives and Guide to Talking Points
- 7 – Cover Essay: Jack Gorman
- 15 – Letter from the Editor Myrna M. Weissman, PhD The Clinical Face of Economics: The Case of Schizophrenia
- 16 – 30 Days Pharmacoeconomic news of the last 30 days Cost is a Major Healthcare Concern for Most People, Study: Low Income African American Women Need, More Information on Menopause, Once-A-Day Adderall for Attention-Deficit/Hyperactivity Disorder, Food and Drug Administration Approves, Levetiracetam as Antiepileptic, Eskalith Shortage Sparks Alternatives
- 18 – Winners & Losers
- 21 – Cost & Therapeutics Commentary by David Williamson, PhD The real-world costs of treating obesity
- 22 – FDA Alert: Prescription Changes and Recalls
- 24 – The TEN Clinical Trial Alert & Guide to Indigent Drug Services A state-by-state resource of open trials for major depression and a list of industry sponsored patient assistance medication programs
- 30 – TEN Marketplace: CNS Agents and New Indications in Development
- 33 – TEN Profile Understanding smoking behavior
- 39 – The Role of the National Alliance for the Mentally Ill in Reversing the Economic Burden of Mental Illness – Laurie Flynn, Peter J. Weiden, MD
- 42 – The Cost of Schizophrenia: Focus on Cognitive and Occupational Dysfunction – Philip D. Harvey, PhD, Susan R. McGurk, PhD
- 51 – Human and Economic Costs of Schizophrenia: A Case Study of the Impact of Newer Antipsychotics – Seth A. Rafal, MD, MS, Ming T. Tsuang, MD, PhD
- 56 – Pharmacologic Treatment of Schizophrenia – John M. Kane, MD
- 65 – The Economic Implications of Schizophrenia: A Pharmacist’s Perspective – Julia E. Vertrees, PharmD, BCPP
Leave A Comment